{"id":51515,"date":"2022-12-02T17:02:46","date_gmt":"2022-12-02T16:02:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-bacteriophage-therapy-market-report-2022-looming-threat-of-antimicrobial-resistance-drives-research-growth-researchandmarkets-com\/"},"modified":"2022-12-02T17:02:46","modified_gmt":"2022-12-02T16:02:46","slug":"global-bacteriophage-therapy-market-report-2022-looming-threat-of-antimicrobial-resistance-drives-research-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-bacteriophage-therapy-market-report-2022-looming-threat-of-antimicrobial-resistance-drives-research-growth-researchandmarkets-com\/","title":{"rendered":"Global Bacteriophage Therapy Market Report 2022: Looming Threat of Antimicrobial Resistance Drives Research & Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography: Industry Trends and Global Forecasts, 2022-2035”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nAntimicrobial resistance (AMR) has been identified as one of the greatest threats to public health. According to the Centers of Disease Control and Prevention, more than 2.8 million cases of AMR infections are identified in the United States on an annual basis, leading to death of more than 35,000 people.\n<\/p>\n

\nFurther, World Health Organization (WHO) has estimated that, by 2050, the increasing burden of such infections is expected to increase the healthcare expenditure by USD 1.2 trillion, annually. To address this situation, WHO has developed a global action plan for raising public awareness, reducing the incidence of infections, and optimizing the use of antimicrobial drugs, paving the way for the development of alternative anti-infectious modalities.\n<\/p>\n

\nOne such example of these modalities includes bacteriophage therapies. These therapeutics have been used in healthcare for over a century, providing an alternative approach to target the disease-causing multi-drug resistant bacteria; however, their use has been limited. With the growing need for therapies targeting AMR infections, bacteriophage therapy are now gaining more traction. These therapeutics tend to cause minimal drug toxicity, replicate themselves at the site of action, have reduced side-effects, and have the potential to self-decompose when the infection causing bacteria have been exterminated.\n<\/p>\n

\nGiven the afore-mentioned advantages of bacteriophage therapy and promising insights from the ongoing research, various clinical trials have been registered for the clinical evaluation of bacteriophage therapies. In fact, with the widespread participation of stakeholders in the research and development of bacteriophage therapy, clinical studies evaluating bacteriophage therapy have increased at a growth rate of more than 30% over the last few years.\n<\/p>\n

\nMoreover, the volume of affiliated scientific literature (2,200+ related publications since 2018) has also increased, demonstrating the growing popularity of bacteriophage therapy and related technologies. Given the encouraging results, this domain has piqued the interest of many private and public investors who have invested more than USD 1 billion over the last few years. With increasing R&D efforts, promising clinical data, and financial support from investors, we anticipate the bacteriophage therapy market to witness notable growth in the mid to long term.\n<\/p>\n

\nScope of the Report<\/strong>\n<\/p>\n